List of Excipients in Branded Drug ACEON

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
XOMA (US) LLC	ACEON	perindopril erbumine	76234-000	CELLULOSE, MICROCRYSTALLINE
XOMA (US) LLC	ACEON	perindopril erbumine	76234-000	LACTOSE
XOMA (US) LLC	ACEON	perindopril erbumine	76234-000	MAGNESIUM STEARATE

ACEON Excipient Strategy and Commercial Opportunities for Perindopril Erbumine

Last updated: September 25, 2026

ACEON is the former U.S. brand for perindopril erbumine, an angiotensin-converting enzyme inhibitor used to treat hypertension and reduce cardiovascular risk. The main commercial opportunity is not brand exclusivity. It is differentiated generic development based on excipient control, improved moisture stability, alternative dosage forms, combination products, and supply advantages.

The strongest near-term strategy is a stable, conventional immediate-release tablet with a robust dissolution profile and a lactose-free option. More differentiated opportunities include orally disintegrating tablets, fixed-dose combinations with indapamide or amlodipine, and products designed for markets where perindopril remains commercially established.

What is ACEON and which active ingredient does it contain?

ACEON contains perindopril erbumine, the erbumine salt of perindopril. Perindopril is a prodrug converted in vivo to perindoprilat, the pharmacologically active ACE-inhibiting metabolite.

Attribute	ACEON
Active ingredient	Perindopril erbumine
Therapeutic class	ACE inhibitor
U.S. dosage form	Immediate-release oral tablets
Historical strengths	2 mg, 4 mg, and 8 mg
Primary indication	Hypertension
Original U.S. sponsor	Solvay Pharmaceuticals
U.S. regulatory pathway	New Drug Application 19-936
Commercial status	Brand product no longer represents a meaningful U.S. exclusivity barrier
Primary development opportunity	Generic and differentiated oral solid dosage products

Perindopril erbumine is a low-dose, high-value active pharmaceutical ingredient relative to tablet mass. This gives manufacturers broad formulation flexibility. The formulation challenge is less about loading and more about controlling tablet uniformity, moisture exposure, dissolution, and chemical stability.

What excipients are used in ACEON tablets?

The U.S. ACEON labeling identifies conventional tablet excipients, including lactose, microcrystalline cellulose, magnesium stearate, colloidal silicon dioxide, and other formulation-specific processing or coloring components depending on strength and presentation.[1]

The historical formulation is consistent with a direct-compression or dry-granulation approach:

Excipient category	Likely function	Commercial relevance
Lactose	Diluent and compressibility aid	Creates a lactose-free differentiation opportunity
Microcrystalline cellulose	Filler, binder, and compaction aid	Supports tablet hardness and content uniformity
Colloidal silicon dioxide	Glidant and moisture-management aid	Improves powder flow at low API loading
Magnesium stearate	Lubricant	Excess use can slow wetting and dissolution
Colorants or coating components	Strength identification and appearance	May create market-specific or allergen concerns

The exact inactive-ingredient profile must be controlled against the applicable reference product and regulatory filing. Generic developers should not assume that a historical brand excipient system is optimal for current manufacturing equipment or target markets.

Which excipient attributes matter most?

The critical material attributes are particle-size distribution, bulk density, moisture content, flowability, lubricant sensitivity, and compatibility with the perindopril erbumine salt.

Perindopril products require particular attention to:

• Low-dose content uniformity
• API segregation during blending
• Moisture-related degradation
• Lubrication time and magnesium stearate level
• Tablet disintegration
• Dissolution across physiological pH conditions
• Packaging protection against humidity
• Granule or powder flow during high-speed compression

A formulation with excessive lubricant or insufficient wetting can produce a slower dissolution profile even when tablet hardness is acceptable. A high-moisture excipient system can complicate stability and packaging requirements.

How should a generic ACEON excipient strategy be designed?

The preferred first-line strategy is a simple, low-risk immediate-release tablet that uses well-established compendial excipients and avoids unnecessary formulation complexity.

Strategy 1: Reference-aligned lactose formulation

A reference-aligned tablet can use lactose, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate. This approach minimizes formulation novelty and is suitable when the objective is rapid regulatory approval and low manufacturing cost.

Advantages include:

• Established excipient safety profile
• Familiar tablet-processing behavior
• Straightforward scale-up
• Low development cost
• Lower risk of dissolution divergence

The main limitation is limited differentiation. Lactose intolerance concerns, excipient labeling preferences, and institutional purchasing specifications may restrict some buyers.

Strategy 2: Lactose-free tablet

A lactose-free product can replace lactose with mannitol, anhydrous dibasic calcium phosphate, partially pregelatinized starch, low-substituted hydroxypropyl cellulose, or additional microcrystalline cellulose.

A practical lactose-free platform may combine:

• Microcrystalline cellulose for compaction
• Mannitol for mouthfeel and tablet mass
• Crospovidone or croscarmellose sodium for disintegration
• Colloidal silicon dioxide for flow
• Magnesium stearate at a controlled concentration

Mannitol is attractive for orally disintegrating and chewable concepts but can increase cost. Dibasic calcium phosphate improves hardness but may affect dissolution and is less suitable for very rapid-disintegration products. Starch-based systems can offer cost benefits but may require tighter moisture controls.

Strategy 3: Low-moisture formulation

A low-moisture formulation is appropriate when stability data show sensitivity to water activity or when the product will be distributed in hot and humid climates.

Potential design features include:

• Anhydrous or low-moisture diluents
• Controlled-humidity manufacturing
• High-barrier aluminum-aluminum blister packaging
• Desiccant-containing bottles
• Moisture-qualified container-closure systems
• Reduced aqueous processing

This strategy may increase packaging cost but can improve shelf-life consistency. Packaging can be a more effective commercial differentiator than an unconventional excipient because it directly addresses distribution conditions.

Strategy 4: Orally disintegrating tablet

Perindopril’s low dose makes it technically suitable for an orally disintegrating tablet. The product could target elderly patients, patients with dysphagia, and adherence-sensitive hypertension populations.

A typical ODT platform would use:

• Mannitol or a mannitol-cellulose blend
• Crospovidone, croscarmellose sodium, or sodium starch glycolate
• A highly efficient lubricant
• Flavoring or taste-masking components
• Direct compression or specialized granulation

The main technical risk is taste. ACE inhibitors can have an unpleasant taste profile, so taste masking may require polymer coating, ion-exchange resins, flavor systems, or a rapidly swallowed porous tablet. The product must meet applicable disintegration, friability, dissolution, and packaging requirements.

An ODT may also face a higher clinical and regulatory burden than a conventional generic tablet if the formulation materially changes administration characteristics or requires additional labeling claims.

What formulations are protected by ACEON-related patents?

The commercial protection around historical ACEON tablets is materially weaker than it was during the brand’s market period. Perindopril and perindopril erbumine have been marketed internationally for decades, and basic composition-of-matter and conventional tablet protection are no longer the principal barriers to entry.

Potentially relevant intellectual-property categories include:

IP category	Relevance to ACEON products
Perindopril composition patents	Historical protection; generally expired or commercially weak
Erbumine salt patents	Historical salt protection; geographic status must be checked
Polymorph or solid-form patents	Could matter for a specific API manufacturing route
Process patents	May affect API cost or impurity control
Combination-product patents	Relevant to perindopril plus indapamide or amlodipine
Formulation patents	Relevant to ODT, sustained-release, taste-masked, or stability-enhanced products
Method-of-use patents	May cover particular cardiovascular populations or dosing regimens
Manufacturing patents	May create supply or freedom-to-operate issues in selected jurisdictions

The U.S. Orange Book should be used to verify current listed patents and exclusivities for the applicable NDA and any abbreviated new drug applications.[2] A historical absence of meaningful brand patents does not eliminate freedom-to-operate risk for a new formulation or combination product.

When did ACEON lose exclusivity?

ACEON’s original U.S. exclusivity period ended long ago. The commercial question is therefore generic availability, not the timing of first generic entry.

The relevant regulatory distinctions are:

Exclusivity type	ACEON relevance
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not the principal protection for ACEON
Pediatric exclusivity	No current commercial significance
Brand patent exclusivity	Historical protection; no longer the main market barrier
Formulation exclusivity	Depends on separately approved product claims
Generic exclusivity	Depends on individual ANDA approvals and Paragraph IV events

No current commercial strategy should rely on ACEON brand exclusivity. The opportunity depends on product economics, API access, regulatory execution, and channel selection.

Which companies are challenging ACEON, and what is the Paragraph IV risk?

Perindopril erbumine is a genericized product rather than a leading current U.S. patent-challenge market. Paragraph IV risk is therefore likely to be limited to any remaining listed patents associated with a particular formulation, method of use, or combination product.

An ANDA applicant using Paragraph IV certification could challenge a listed patent by asserting that the patent is invalid, unenforceable, or not infringed. The commercial consequences would depend on:

• Whether the Orange Book lists an active patent
• Whether the patent covers the proposed product or only a method of use
• Whether the applicant seeks a first-to-file advantage
• Whether the NDA holder files suit within the statutory period
• Whether a 30-month stay applies
• Whether a settlement restricts launch timing

For a conventional perindopril erbumine tablet, the greater risk is usually regulatory and commercial rather than patent litigation. For an ODT or combination product, formulation and use patents require a more detailed claim-by-claim review.

What is the FDA regulatory status of ACEON and its generics?

ACEON was approved as an NDA product for hypertension. Generic perindopril erbumine tablets require ANDA approval demonstrating pharmaceutical equivalence and bioequivalence to the relevant reference product or regulatory standard.[3]

Key FDA considerations include:

• Same active ingredient and dosage form
• Equivalent strength
• Comparable labeling, subject to approved differences
• Demonstrated dissolution performance
• Bioequivalence under the applicable FDA product-specific guidance
• Adequate stability data
• Compliance with current good manufacturing practice
• Acceptable inactive ingredients for the route and dosage form

The reference-listed-drug status and current marketing status should be confirmed in the FDA Orange Book and Drugs@FDA databases before committing to a U.S. launch plan.[2,4]

For an ODT, chewable, or other differentiated product, the sponsor may need a separate regulatory strategy. A 505(b)(2) application could be relevant where the product differs materially from the conventional reference product and relies partly on existing safety or efficacy findings.

What generic launch risks exist for perindopril erbumine?

The main launch risks are low market size, API procurement, reimbursement pressure, and formulation economics.

Market-size risk

Perindopril has stronger historical and current commercial positions in several non-U.S. markets than in the United States. A U.S.-only generic launch may not generate sufficient volume unless the manufacturer has an existing cardiovascular portfolio or a low-cost supply platform.

API and salt-form risk

The sponsor must qualify perindopril erbumine suppliers for:

• Assay and related substances
• Water content
• Particle-size distribution
• Bulk density
• Residual solvents
• Nitrosamine and elemental-impurity controls
• Polymorphic or solid-state consistency
• Stability under transport conditions

The API salt form can affect powder flow, dissolution, and content uniformity. Changing suppliers after approval may require comparability work and regulatory filings.

Price erosion

Perindopril is exposed to standard generic price erosion. A conventional tablet is likely to become a low-margin product unless the company controls manufacturing cost, has a differentiated channel, or bundles the product with other cardiovascular medicines.

Supply-chain risk

Low-volume products can experience shortages when only a small number of suppliers remain active. A commercial plan should qualify at least two API sources where feasible and maintain alternative packaging configurations.

How does ACEON compare with other ACE inhibitors?

Perindopril competes with lisinopril, enalapril, ramipril, benazepril, and other ACE inhibitors. Its commercial differentiation is based less on excipient novelty than on dosing familiarity, combination products, and international prescribing patterns.

Product	Active ingredient	Excipient opportunity	Commercial position
ACEON	Perindopril erbumine	Lactose-free tablet, ODT, combinations	Niche generic opportunity
Prinivil/Zestril	Lisinopril	Broad generic platform, ODT potential	Large established generic market
Vasotec	Enalapril maleate	Conventional tablets and solutions	Mature generic market
Altace	Ramipril	Capsules, tablets, combinations	Mature cardiovascular market
Lotensin	Benazepril HCl	Tablets, combination products	Mature generic market

Perindopril may be more attractive as part of a broader portfolio than as a standalone U.S. launch. A manufacturer with indapamide, amlodipine, or other antihypertensive products can create a more efficient commercial offering.

What licensing and partnership opportunities exist?

Licensing opportunities are most credible in four areas:

1. Regional commercialization rights in markets where perindopril remains widely prescribed.
2. Contract manufacturing of tablets for established international suppliers.
3. Fixed-dose combination development involving indapamide or amlodipine.
4. Differentiated dosage forms such as ODTs, pediatric-friendly liquids, or moisture-protected tablets.

A licensing deal should allocate responsibility for API qualification, stability commitments, pharmacovigilance, serialization, regulatory maintenance, and shortage management. The asset is more valuable when it includes an approved dossier, validated manufacturing process, and established distribution rather than only a formulation concept.

How strong is the patent estate for ACEON?

The historical ACEON patent estate is weak as a barrier to conventional generic entry. The strongest remaining IP opportunities are likely to arise from newly developed formulations, combinations, manufacturing processes, or jurisdiction-specific method-of-use claims.

Patent strategy	Expected commercial value
Conventional perindopril tablet	Low
Lactose-free formulation	Low to moderate unless technically distinctive
Moisture-stable formulation	Moderate if supported by unexpected stability results
ODT with taste masking	Moderate to high if claims are narrow but enforceable
Perindopril-indapamide combination	Moderate, subject to prior-art review
Perindopril-amlodipine combination	Moderate, subject to prior-art review
Novel API process or impurity-control method	Moderate to high for manufacturing control
Broad use patent	Difficult to sustain where clinical use is established

A formulation patent should be built around measurable technical advantages, such as improved stability, dissolution under discriminatory conditions, reduced degradation products, or improved patient usability. Simple substitution of one standard diluent for another is unlikely to create strong protection without unexpected results.

What is the revenue exposure and commercial opportunity?

ACEON itself has limited current U.S. brand revenue exposure. The addressable opportunity is the broader perindopril market, including generic tablets, international markets, and combinations.

The most defensible commercial models are:

• Low-cost generic supply for high-volume international markets
• Portfolio bundling with other antihypertensive products
• Premium lactose-free or moisture-protected tablets
• ODT products for adherence-sensitive populations
• Combination products that reduce pill burden
• Contract manufacturing for regional licensees

A conventional U.S. generic launch should be treated as a volume and portfolio product, not a premium standalone asset. A differentiated product requires stronger evidence of patient, prescriber, payer, or supply-chain value.

Key Takeaways

• ACEON is the historical U.S. brand for perindopril erbumine.
• Its original exclusivity is no longer the main commercial issue.
• A conventional immediate-release tablet remains the lowest-risk development route.
• Lactose-free, low-moisture, and ODT formulations offer the clearest excipient-led differentiation.
• The most important technical controls are content uniformity, moisture management, lubrication, dissolution, and API solid-state consistency.
• Conventional perindopril tablet patents provide limited protection against generic entry.
• Combination products with indapamide or amlodipine may offer better commercial economics than a standalone tablet.
• U.S. launch economics are likely to depend on portfolio scale, API cost, and distribution efficiency.
• Orange Book, Drugs@FDA, and current national registers should be reviewed before filing or licensing decisions.

FAQs

Is ACEON still protected by patents?

ACEON’s historical brand protection is no longer the principal barrier to conventional perindopril erbumine generic entry. Current Orange Book listings must be checked for any remaining product-specific patents.

What is the best lactose-free excipient for perindopril tablets?

Mannitol is attractive for lactose-free and orally disintegrating products. Microcrystalline cellulose and anhydrous dibasic calcium phosphate are also viable, but the final choice depends on dissolution, hardness, moisture, and manufacturability data.

Can perindopril be developed as an orally disintegrating tablet?

Yes. Its low dose is compatible with an ODT platform. Taste masking, moisture protection, disintegration performance, and packaging are the main development issues.

Is perindopril a good candidate for a fixed-dose combination?

Yes. Perindopril-indapamide and perindopril-amlodipine combinations are commercially logical because they can reduce pill burden and support differentiated cardiovascular portfolios.

What is the main manufacturing barrier for generic ACEON?

The principal barriers are low-dose content uniformity, API supply consistency, moisture control, dissolution matching, and the limited margin available in a mature generic market.

References

1. U.S. Food and Drug Administration. (n.d.). ACEON (perindopril erbumine) tablets: Prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA.
4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs.
5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. USP Convention.